Discordant diagnostic criteria for pneumonia in COPD trials: a review
暂无分享,去创建一个
Meilan K. Han | F. Martinez | G. Criner | D. Halpin | Dave Singh | C. Crim | M. Dransfield | M. Bafadhel | R. Russell | M. Zysman | R. Wise | D. Lipson | Nicola C. Day | D. Maselli | D. Midwinter | P. Lange | M. Han
[1] Jian Sun,et al. Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials , 2021, Frontiers in Pharmacology.
[2] M. Miravitlles,et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD , 2021, European Respiratory Review.
[3] T. van der Poll,et al. Pneumonia , 2021, Nature Reviews Disease Primers.
[4] F. Martinez,et al. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial , 2020, Pulmonary Therapy.
[5] K. Torén,et al. Inhaled Corticosteroids Use and Risk of Invasive Pneumococcal Disease in a Population-based Study , 2020, Annals of the American Thoracic Society.
[6] S. Li,et al. Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis , 2020, COPD.
[7] P. Dorinsky,et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.
[8] P. Dorinsky,et al. Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD , 2020, ERJ Open Research.
[9] Pneumonia in exacerbations of COPD: what is the clinical significance? , 2020, ERJ Open Research.
[10] V. Novack,et al. The Association of Glucocorticosteroid Treatment with WBC Count in Patients with COPD Exacerbation , 2019, Journal of clinical medicine.
[11] M. Fine,et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America , 2019, American journal of respiratory and critical care medicine.
[12] J. Wyatt,et al. Level of accuracy of diagnoses recorded in discharge summaries: A cohort study in three respiratory wards , 2018, Journal of evaluation in clinical practice.
[13] S. Suissa,et al. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.
[14] P. Dorinsky,et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. , 2018, The Lancet. Respiratory medicine.
[15] P. Dorinsky,et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study , 2018, European Respiratory Journal.
[16] J. Wedzicha,et al. Long‐Term Triple Therapy De‐escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double‐Blind, Triple‐Dummy Clinical Trial , 2018, American journal of respiratory and critical care medicine.
[17] Xuejun Guo,et al. Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two "real-life" studies. , 2018, Journal of thoracic disease.
[18] A. Anzueto,et al. Pneumonia in Patients with Chronic Obstructive Pulmonary Disease , 2018, Tuberculosis and respiratory diseases.
[19] M. Niederman,et al. Treatment guidelines for community-acquired pneumonia , 2018, Annals of Research Hospitals.
[20] J. Hurst. Consolidation and Exacerbation of COPD , 2018, Medical sciences.
[21] Meilan K. Han,et al. Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.
[22] N. Roche,et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.
[23] Global and Japanese regional variations in radiologist potential workload for computed tomography and magnetic resonance imaging examinations , 2018, Japanese Journal of Radiology.
[24] D. Tashkin,et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. , 2017, Respiratory medicine.
[25] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. , 2017, Respiratory medicine.
[26] M. Serra-Prat,et al. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies , 2017, Respiration.
[27] A. Papi,et al. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial , 2017, International journal of chronic obstructive pulmonary disease.
[28] Dave Singh,et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.
[29] N. Coombs,et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records , 2017, International journal of chronic obstructive pulmonary disease.
[30] Catherine Harvey,et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. , 2016, The New England journal of medicine.
[31] I. Pavord,et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.
[32] C. Vogelmeier,et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study , 2016, European Respiratory Journal.
[33] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[34] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[35] C. Roberts,et al. The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit , 2015, PloS one.
[36] Mike Clarke,et al. Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use , 2015, PLoS medicine.
[37] Nuofu Zhang,et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD , 2015, International journal of chronic obstructive pulmonary disease.
[38] N. Zhong,et al. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial , 2015, Current medical research and opinion.
[39] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.
[40] A. Papi,et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD , 2014, European Respiratory Journal.
[41] M. Decramer,et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.
[42] M. Dransfield,et al. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation , 2014, Respiratory Research.
[43] P. Jones,et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. , 2014, Respiratory medicine.
[44] Kayleigh Kew,et al. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[45] David Tarpey,et al. Accuracy of diagnosis of pneumonia in an UK hospital participating in the advancing quality initiative , 2013 .
[46] F. Martinez,et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.
[47] E. Kerwin,et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. , 2013, Respiratory medicine.
[48] B. Beghé,et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD , 2013, European Respiratory Journal.
[49] F. Martinez,et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. , 2013, Respiratory medicine.
[50] E. Bateman,et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.
[51] I. Mitchell,et al. P17 The Accuracy of a Diagnosis of Pneumonia in a UK Teaching Hospital , 2012, Thorax.
[52] Jeremy S. Brown. Community-acquired pneumonia. , 2012, Clinical medicine.
[53] J. Wedzicha,et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. , 2012, Respiratory medicine.
[54] S. D. Lee,et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. , 2012, Respiratory medicine.
[55] E. Kerwin,et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial , 2012, International journal of chronic obstructive pulmonary disease.
[56] E. Kerwin,et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD , 2012, International journal of chronic obstructive pulmonary disease.
[57] A. Sharafkhaneh,et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.
[58] S. Rennard,et al. Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.
[59] S. Rennard,et al. Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease , 2008, Drugs.
[60] T. Seemungal,et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.
[61] P. Kuna,et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. , 2010, Respiratory medicine.
[62] W. Lim,et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009 , 2009, Thorax.
[63] P. Jones,et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.
[64] Yoon K Loke,et al. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.
[65] A. Anzueto,et al. Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.
[66] A. Anzueto,et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.
[67] S. Sethi,et al. Optimizing antibiotic selection in treating COPD exacerbations , 2008, International journal of chronic obstructive pulmonary disease.
[68] S. Rennard,et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. , 2008, Drugs.
[69] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[70] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[71] W. Thompson,et al. The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] Amy Berrington de González,et al. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries , 2004, The Lancet.
[73] S. Hurd,et al. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.
[74] M. Leinonen,et al. Pneumonic vs Nonpneumonic Acute Exacerbations of COPD , 2002, Chest.
[75] M. Fine,et al. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. , 1997, JAMA.